Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer

Krishnan K. Mahadevan, Allison M. Dyevoich, Yang Chen, Bingrui Li, Hikaru Sugimoto, Amari M. Sockwell, Kathleen M. McAndrews, Lakshmi Kavitha Sthanam, Huamin Wang, Shabnam Shalapour, Stephanie S. Watowich, Raghu Kalluri

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Inflammation and tissue damage associated with pancreatitis can precede or occur concurrently with pancreatic ductal adenocarcinoma (PDAC). We demonstrate that in PDAC coupled with pancreatitis (ptPDAC), antigen-presenting type I conventional dendritic cells (cDC1s) are specifically activated. Immune checkpoint blockade therapy (iCBT) leads to cytotoxic CD8+ T cell activation and elimination of ptPDAC with restoration of life span even upon PDAC rechallenge. Using PDAC antigen-loaded cDC1s as a vaccine, immunotherapy-resistant PDAC was rendered sensitive to iCBT with elimination of tumors. cDC1 vaccination coupled with iCBT identified specific CDR3 sequences in the tumor-infiltrating CD8+ T cells with potential therapeutic importance. This study identifies a fundamental difference in the immune microenvironment in PDAC concurrent with, or without, pancreatitis and provides a rationale for combining cDC1 vaccination with iCBT as a potential treatment option.

Original languageEnglish (US)
Pages (from-to)eadh4567
JournalScience (New York, N.Y.)
Volume384
Issue number6703
DOIs
StatePublished - Jun 28 2024

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer'. Together they form a unique fingerprint.

Cite this